Profiling of TOC-Microsatellite Loci at 17q25 in OSCC Patients with Therapeutic Validation
Authors/Creators
- 1. Associate Professor, Department of Biochemistry & Head, Research & Development, Hind Institute of Medical Sciences, Ataria, Sitapur, UP, India
- 2. Professor, Department of Radiotherapy, King George's Medical University, Lucknow, Uttar Pradesh, India
Description
Abstract: Treatment strategies for oral cancer are still primarily based on tumor-node-metastasis classification. A variety of prognostic biological markers correlated to survival have been described over the years, but very few of these have been tested for prognostic accuracy. The advent of genome-wide screening methods such as comparative genomic hybridization, Microarray, microsatellites and SNPs have opened up new possibilities to catalogue chromosomal aberrations, point mutation for disease diagnosis as well as therapeutic validation. Aberration of the Tylosis Oesophageal Cancer (TOC ) gene mapped to chromosome 17q25 has been recognized as a genetic marker for the development of Oesophageal, Breast and Ovarian cancer. Material & Methods: A total of 26 Microsatellite markers at 17q25 were examined in 150 OSCC patients treated with cisplatin and capecitabine to establish genetic marker for early detection and therapeutic validation. A total of 150 primary tumor tissues, and corresponding blood samples from patients attending the Chhatrapati Shahuji Mahraj Medical University Lucknow from 2003 to 2006, were collected. The tissue samples were obtained, either at the time of investigative biopsy or during the time of the surgical resection of the lesions. Results: Overall incidence of LOH/MSI was 40%±20.84 with the frequency of LOH and MSI of individual markers ranged from 12-93%. LOH was relatively more frequently detected at five loci, namely D17S1817 (57.33%), D17S1864 (81.33%), D17S1603 (68.66%), D17S1602 (93.33%), D17S929 (64%). Low incidence of LOH and MSI was observed in D17S2238 (20.7%) and D17S926 (12.66%) and D17S2101 (18.7%). Conclusion: To our knowledge, this is the first report suggesting an association between allelic loss at D9S1602 & D17S1864 on TOC loci and recurrence in OSCC from India in patients treated with Cisplatin & Capecitabine.
Abstract (English)
Abstract: Treatment strategies for oral cancer are still primarily based on tumor-node-metastasis classification. A variety of prognostic biological markers correlated to survival have been described over the years, but very few of these have been tested for prognostic accuracy. The advent of genome-wide screening methods such as comparative genomic hybridization, Microarray, microsatellites and SNPs have opened up new possibilities to catalogue chromosomal aberrations, point mutation for disease diagnosis as well as therapeutic validation. Aberration of the Tylosis Oesophageal Cancer (TOC ) gene mapped to chromosome 17q25 has been recognized as a genetic marker for the development of Oesophageal, Breast and Ovarian cancer. Material & Methods: A total of 26 Microsatellite markers at 17q25 were examined in 150 OSCC patients treated with cisplatin and capecitabine to establish genetic marker for early detection and therapeutic validation. A total of 150 primary tumor tissues, and corresponding blood samples from patients attending the Chhatrapati Shahuji Mahraj Medical University Lucknow from 2003 to 2006, were collected. The tissue samples were obtained, either at the time of investigative biopsy or during the time of the surgical resection of the lesions. Results: Overall incidence of LOH/MSI was 40%±20.84 with the frequency of LOH and MSI of individual markers ranged from 12-93%. LOH was relatively more frequently detected at five loci, namely D17S1817 (57.33%), D17S1864 (81.33%), D17S1603 (68.66%), D17S1602 (93.33%), D17S929 (64%). Low incidence of LOH and MSI was observed in D17S2238 (20.7%) and D17S926 (12.66%) and D17S2101 (18.7%). Conclusion: To our knowledge, this is the first report suggesting an association between allelic loss at D9S1602 & D17S1864 on TOC loci and recurrence in OSCC from India in patients treated with Cisplatin & Capecitabine.
Files
IJPCR,Vol15,Issue4,Article203.pdf
Files
(760.9 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:fad88b0588450450338966093067fd84
|
760.9 kB | Preview Download |
Additional details
Dates
- Accepted
-
2023-03-30
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/15/IJPCR,Vol15,Issue4,Article203.pdf
- Development Status
- Active
References
- 1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55: 74–108. 2. Kallioniemi A, CGH microarrays and cancer. Curr Opin Biotechnol. 2008, 19: 36–40. 3. Lippman SM, Hong WK, Molecular markers of the risk of oral cancer. N Engl J Med. 2001; 344: 1323–1326. 4. Klussmann JP, Mooren JJ, Lehnen M, Claessen SM, Stenner M, et al. Genetic signatures of HPV-related and unrelated oropharyngeal carcinoma and their prognostic implications. Clin Cancer Res. 2009;15: 1779–1786. 5. Trask D, Wolf G, Bradford C, et al. Expression of Bcl-2 family proteins in advanced laryngeal squamous cell carcinoma: correlation with response to chemotherapy and organ preservation. Laryngoscope. 2002; 112:638–44. 6. Bradford CR, Zhu S, Wolf GT, et al. Overexpression of p53 predicts organ preservation using induction chemotherapy and radiation in patients with advanced laryngeal cancer. Otolaryngol Head Neck Surg. 1995; 113:408 –12. 7. Bradford C, Zhu S, Ogawa H, et al. p53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma cell lines. Head Neck. 2003; 25:654–61. 8. Akervall J, Kurnit DM, Adams M, et al. Overexpression of cyclin D1 correlates with sensitivity to cisplatin in squamous cell carcinoma cell lines of the head and neck. Acta Otolaryngol. 2004; 124:851– 7. 9. Akervall J, Guo X, Qian CN, Schoumans J, Leeser B, Kort E, Cole A, Resau J, Bradford C, Carey T, Wennerberg J, Anderson H, Tennvall J, Teh BT. Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients. Clin Cancer Res. 2004 Dec 15;10(24):8204-13. 10. Christiana ruhrberg, jill a. Williamson, denise sheer, and fionam. Watt. Chromosomal Localisation of the Human Envoplakin Gene (EVPL) to the Region of the Tylosis Oesophageal Cancer Gene (TOCG) on 17q25. Genomics. 1996; 37: 381–385. 11. Moodley R, Reddi A, Chetty R, Naidoo R. Abnormalities of chromosome 17 in oesophageal cancer. J Clin Pathol. 2007 Sep; 60(9):990-4. 12. Naidoo R, Ramburan A, Reddi A, et al. Aberrations in the mismatch repair genes and the clinical impact on oesophageal squamous carcinomas from a high incidence area in South Africa. J Clin Pathol. 2005; 583:281–4. 13. Koichi Fukino, Aritoshi Iida, Akira Teramoto, Goi Sakamoto, Fujio Kasumi,Yusuke Nakamura and Mitsuru Emi. Frequent Allelic Loss at the TOC Locus on 17q25.1 in Primary Breast Cancers. GENES, Chromosomes & Cancer. 1999; 24:345–350. 14. Yukio Yamano, Katsuhiro Uzawa, Kengo Saito, Dai Nakashima, Atsushi Kasamatsu, Hirofumi Koike. Identification of cisplatin-resistance related genes in head and neck squamous cell carcinoma. Int. J. Cancer. 2010; 126: 437–449. 15. Murali A, Sailasree R, Sebastian P, Rejnish Kumar R, Varghese BT, Kannan S. Loss of heterozygosity of D9S162: molecular predictor for treatment response in oral carcinoma. Oral Oncol. 2011; 47(7):571-6. 16. Jan Akervall, Xiang Guo, Chao-Nan Qian, Jacqueline Schoumans, BrandonLeeser, Eric Kort, Andrew Cole, James Resau, Carol Bradford, Genetic and Expression Profiles of Squamous Cell Carcinoma of the Head and Neck Correlate with Cisplatin Sensitivity and Resistance in Cell Lines and Patients. Clinical Cancer Research. 2004; 10, 8204–8213. 17. Charara M, Edmonston TB, Burkholder S, Walters R, Anne P, Mitchell E, Fry R, Boman B, Rose D, Fishel R, Curran W, Palazzo J. Microsatellite status and cell cycle associated markers in rectal cancer patients undergoing a combined regimen of 5-FU and CPT-11 chemotherapy and radiotherapy. Anticancer Res. 2004; 24(5B): 3161-7. 18. Kelsell DP, Risk JM, Leigh IM, Stevens HP, Ellis A, Hennies HC, Reis A, Weissenbach J, Bishop DT, Spurr NK, Field JK. Close mapping of the focal nonepidermolytic palmoplantar keratoderma (PPK) locus associated with oesophageal cancer (TOC). Hum Mol Genet. 1996; 5(6):857-60. 19. Langan JE, Cole CG, Huckle EJ, Byrne S, McRonald FE, Rowbottom L, Ellis A, Shaw JM, Leigh IM, Kelsell DP, Dunham I, Field JK, Risk JM. Novel microsatellite markers and single nucleotide polymorphisms refine the tylosis with oesophageal cancer (TOC) minimal region on 17q25 to 42.5 kb: sequencing does not identify the causative gene. Hum Genet. 2004 May;114(6):534-40. 20. Ashazila MJ, Kannan TP, Venkatesh RN, Hoh BP. Microsatellite instability and loss of heterozygosity in oral squamous cell carcinoma in Malaysian population. Oral Oncol. 2011;47(5):358-64. 21. Kim ST, Lee J, Park SH, Park JO, Lim HY, Kang WK, Kim JY, Kim YH, Chang DK, Rhee PL, Kim DS, Yun H, Cho YB, Kim HC, Yun SH, Lee WY, Chun HK, Park YS. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemother Pharmacol. 2010 Sep; 66(4): 659-67 22. Harada H, Nagai H, Tsuneizumi M, Mikami I, Sugano S, Emi M. Identification of DMC1, a novel gene in the TOC region on 17q25.1 that shows loss of expression in multiple human cancers. J Hum Genet. 2001; 46(2):90-5. 23. Migaldi M, Sartori G, Rossi G, Cittadini A, Sgambato A. Tumor cell proliferation and microsatellite alterations in human ameloblastoma. Oral Oncol. 2008 Jan; 44(1): 50-60. 24. Ah-See KW, Cooke TG, Pickford IR, Soutar D, Balmain A. An allelotype of squamous carcinoma of the head and neck using microsatellite markers. Cancer Res. 1994; 54(7):1617-21 25. Yaguang, Andrea Formentini, Go Nakajima, Marko Kornmann, Jingfang Ju. Validation of biomarkers associated with 5-fluorouracil and thymidylate synthase in colorectal cancer. Oncology reports. 2008; 19: 257-262, 26. Katherine H. Rak Tkaczuk. Ixabepilone as Monotherapy or in Combination with Capecitabine for the Treatment of Advanced Breast Cancer. Breast Cancer: Basic and Clinical Research 2011:5 1–14. 27. Ten-i Godai, Tetsuji Suda, Nobuhiro Sugano, Kazuhito Tsuchida, Manabu Shiozawa, Hironobu Sekiguchi et al. Identification of colorectal cancer patients with tumors carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5-fluorouracil (5-FU) based postoperative chemotherapy. BMC Cancer. 2009; 9: 420 28. Giovannetti E, Pacetti P, Reni M, Leon LG, Mambrini A, Vasile E, Ghidini M, Funel N, Lucchesi M, Cereda S, Peters GJ, Cantore M. Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated withcombination chemotherapy. Pharmacogenomics. 2011 Dec; 12(12): 1641-52.